

VILNIUS UNIVERSITY

ARVYDAS BARANAUSKAS

THE EFFECTIVENESS OF MYOCARDIAL REVASCULARIZATION IN PATIENTS
WITH DIFFUSE CORONARY ATHEROSCLEROSIS

Summary of doctoral dissertation
Biomedical sciences, medicine (06 B)

Vilnius, 2017

The dissertation has been prepared at Vilnius University during the period 2012–2016.

Scientific Supervisor – Assoc. Prof. Dr. Giedrius Davidavičius (Vilnius University, Biomedical Sciences, Medicine – 06 B).

Dissertation is defended at the Medical Research Council of Vilnius University.

Chairperson – Prof. Dr. Algirdas Utkus (Vilnius University, Biomedical Sciences, Medicine – 06 B).

Members:

Assoc. Prof. Dr. Gintaras Kalinauskas (Vilnius University, Biomedical Sciences, Medicine – 06 B);

Assoc. Prof. Dr. Ramūnas Unikas (Lithuanian University of Health Sciences, Biomedical Sciences, Medicine – 06 B);

Prof. Dr. Arnas Kačeniauskas (Vilnius Gediminas Technical University, Technological Sciences, Informatics Engineering – 07 T);

Dr. Indulis Kumsars (Pauls Stradins Clinical University Hospital, Riga, Latvia, Biomedical Sciences, Medicine – 06 B).

The dissertation will be defended at the open session of the Medical Research Council at 12 p.m. on 27th of June 2017, in the Conference hall of Vilnius University Hospital Santaros Klinikos. Address: Santariškių str. 2, Vilnius, Lithuania.

The summary of the doctoral dissertation was sent on 26th of May 2017.

The dissertation can be viewed in the Vilnius University Library and on the website address: www.vu.lt/lt/naujienos/ivykiu-kalendorius.

VILNIAUS UNIVERSITETAS

ARVYDAS BARANAUSKAS

MIOKARDO REVASKULIARIZACIJOS EFEKTYVUMO ĮVERTINIMAS
VYRAUJANT DIFUZINIAM ATEROSKLEROZINIAM ŠIRDIES VAINIKINIŲ
ARTERIJŲ PAŽEIDIMUI

Daktaro disertacijos santrauka
Biomedicinos mokslai, medicina (06 B)

Vilnius, 2017 metai

Disertacija rengta 2012–2016 metais Vilniaus universitete.

Mokslinis vadovas – doc. dr. Giedrius Davidavičius (Vilniaus universitetas, biomedicinos mokslai, medicina – 06 B)

Disertacija ginama Vilniaus universiteto Medicinos mokslo krypties taryboje:

Pirmininkas – prof. dr. Algirdas Utkus (Vilniaus universitetas, biomedicinos mokslai, medicina – 06 B).

Nariai:

doc. dr. Gintaras Kalinauskas (Vilniaus universitetas, biomedicinos mokslai, medicina – 06 B);

doc. dr. Ramūnas Unikas (Lietuvos sveikatos mokslų universitetas, biomedicinos mokslai, medicina – 06 B);

prof. dr. Arnas Kačeniauskas (Vilniaus Gedimino technikos universitetas, technologijos mokslai, informatikos inžinerija – 07 T);

dr. Indulis Kumsars (Pauls Stradins klinikinė universitetinė ligoninė, Ryga, Latvija, biomedicinos mokslai, medicina – 06 B).

Disertacija bus ginama viešame Medicinos mokslo krypties tarybos posėdyje 2017 m. birželio 27 d. 12 val. Vilniaus universiteto ligoninės Santaros klinikos konferencijų salėje.
Adresas: Santariškių gatvė 2, Vilnius, Lietuva.

Disertacijos santrauka išsiuntinėta 2017 m. gegužės 26 d.

Disertaciją galima peržiūrėti Vilniaus universiteto bibliotekoje ir VU interneto svetainėje adresu: www.vu.lt/lt/naujienos/ivykiu-kalendorius

ABBREVIATIONS

BMS – bare metal stent

DAPT – dual antiplatelet therapy

DES – drug eluting stent

DS – diameter stenosis

FFR – fractional flow reserve

IVUS – intravascular ultrasound

LAD – left anterior descending artery

LLL – late lumen loss

MACE – major adverse cardiovascular events

MLD – minimal luminal diameter

NSD – nominal stent diameter

OCT – optical coherence tomography

PCI – percutaneous coronary intervention

QCA – quantitative coronary angiography

RVD – reference vessel diameter

STEMI – ST-elevation myocardial infarction

SD – standard deviation

TIMI – Thrombolysis In Myocardial Infarction

TVR – target vessel revascularization

1. Introduction

1.1. Clinical relevance

There is still a controversy in the treatment of long coronary lesions. In case of diffuse coronary artery disease the optimal extent of percutaneous coronary intervention (PCI) is not well established and is usually operator dependent. The evaluation of the post-PCI result by angiography alone is not accurate in the majority of the cases when diffuse coronary artery disease is present. There are almost no data on the long term functional result (residual ischemia in the target vessel territory) after PCI on long coronary lesions in the newer generation drug eluting stents (DES) era.

Fractional flow reserve (FFR) guided PCI has been shown to improve clinical outcomes in patients when compared to angiographic guided PCI at long-term follow-up. In patients with stable coronary artery disease the rate of death, myocardial infarction, or urgent revascularization at 2 years among those who underwent FFR-guided PCI with contemporary drug-eluting stents is less than half the rate among patients who received medical therapy alone (1).

There is a growing awareness of the poor accuracy of coronary angiography for identifying lesions responsible for myocardial ischemia and the inaccuracy of noninvasive stress testing, especially in patients with multivessel coronary artery disease (2,3). De Bruyne B et al. reported that in patients with coronary artery stenosis in another vessel, approximately half of coronary arteries without angiographic focal stenosis have a graded, continuous decline in coronary pressure along their length, especially during hyperemia. This decline in pressure was not observed in the normal arteries of subjects without atherosclerosis. The presence and severity of this coronary pressure gradient could not be predicted from the angiogram (4).

The poor correlation between FFR and arterial diameters reflects the failure of standard coronary angiography to account for the hemodynamic effects of diffuse disease (4). Furthermore, there is an increasing body of evidence that FFR measured after PCI is a strong independent predictor of major adverse cardiovascular events (MACE). According to Agarwal SK et al., the use of FFR after PCI in patients undergoing pre-PCI FFR modified treatment in approximately 20% of lesions (5). Pijls et al. have shown that

the higher the post-PCI FFR following bare metal stent implantation, the lower the MACE rate at 6 months follow-up (6). In support of this, a more recent meta-analysis by Johnson et al. again shows that the higher the FFR after PCI, the better the prognosis (7). Specifically, it seems that the optimal PCI result is achieved when the FFR value after PCI is >0.95 , comparable to that found in angiographically normal coronary arteries (8).

Despite hints of the clinical value of post-PCI FFR, it is rarely performed in clinical practice and clinical guidelines and expert consensus documents are silent on the use of post-PCI FFR (9).

Earlier data with bare metal stents and first generation drug eluting stent indicates that the total stent length is associated with a risk of stent restenosis and thrombosis (10–12). First-generation DES have also been associated with the increased rates of very late (>1 year) stent thrombosis (13,14). Long coronary lesion stenting was shown to be associated with increased MACE in the first-generation DES era (15). Reported 2-year MACE rates were highest in patients with long lesions in small vessels (10.4%), intermediate in patients with either long lesions or small vessels but not both (8.2%), and lowest in patients with short lesions in large vessels (5.6%) (16). MACE rates remain remarkably high when long stents are used (16,17). Therefore, we cannot be sure that the functional result achieved after PCI is equally acceptable when long (>30 mm) or ultra long (>50 mm) stenting is carried out.

The assessment of restenosis has traditionally been done using angiographic follow-up or increasingly, clinically driven restenosis. This may not be ideal when we consider that the angiographic result after PCI may not be functionally acceptable. One might speculate that the traditional evaluation of restenosis may well underestimate the actual rates of target vessel revascularization (TVR) especially in long lesions treated with long drug eluting stents.

1.2. Study hypothesis

After stenting long coronary lesions functional revascularization result remains suboptimal ($\text{FFR} \leq 0.8$) despite good angiographic result achieved (residual stenosis $<20\%$).

Because of the diffuse neointimal proliferation in long stented segment, the functional restenosis at follow-up can be measurable in patients without angiographically apparent restenosis.

1.3. The aim of this study

To evaluate functional, angiographic and clinical results of FFR guided PCI on long coronary lesions using 2nd or newer generation DES.

1.4. Study tasks

To evaluate the functional result immediately after PCI and at 9-month follow-up in long coronary lesions treated with long 2nd or newer generation DES.

To ascertain how often a functionally optimal result of FFR>0.95 can be achieved.

To compare the rate of functional and angiographic restenosis at 9-month follow-up.

To evaluate 2-year clinical result after treating long coronary lesions and the influence of the total 2nd or newer generation DES length on long term target vessel revascularization rate.

1.5. What is new

Little is known about the functional (haemodynamic) revascularization effect in patients with diffuse coronary artery disease. Currently there is no study that has used FFR to assess the functional PCI result and restenosis at a long-term follow-up in patients with long coronary lesions in newer generation DES era. The data of this study could help to establish optimal treatment strategies in patients with diffuse coronary atherosclerosis.

2. Methods

This was a prospective, “all comers” single center study. The study protocol was approved by the local Ethics Committee, and informed consent was obtained in all cases. The database was created to store the patient data.

Consecutive patients admitted to Vilnius University Hospital Santaros Klinikos with stable angina pectoris or an acute coronary syndrome were screened for inclusion after coronary angiography and FFR measurement. Patients were included if they had a lesion in a major epicardial vessel where FFR value was ≤ 0.8 and it was envisaged that a stent ≥ 30 mm in length would be necessary. Patients with ST-elevation myocardial infarction (STEMI), in whom long term dual antiplatelet therapy was contraindicated with an expected survival < 1 year, or with an allergy to biolimus, everolimus or zotarolimus, were excluded from the study.

2.1. Coronary angiography, FFR measurement and PCI procedure


For transradial catheterization, an arterial puncture was made by means of the modified Seldinger technique. Once the sheath was in the place, an intra-arterial vasodilator was given (0.1 mg of isosorbide dinitrate). Intravenous heparin was used (usual dose, 70-100 units/kg; maximum total dose, 10000 units). Transfemoral catheterization could be performed if preferred by the operator.

As the access was obtained, after intracoronary administration of 0.1 mg of isosorbide dinitrate, selective coronary angiography was performed in different views (at least two orthogonal views for each segment of the coronary) using hand injections.

The 0.014-inch Pressure Wire (SJM™) was advanced to the tip of the guiding catheter and the pressures were equalized to ensure that the pressure recorded through the guiding catheter and the Pressure Wire were identical at that position. The wire was then advanced into the most distal part of the vessel. After the pressures had been recorded under baseline conditions, coronary hyperemia was induced by the intravenous administration of adenosine (140 mcg/kg/min). FFR was calculated as the ratio of distal coronary pressure to aortic pressure during maximal hyperemia. In the patients, in whom steady-state hyperemia was induced by intravenous adenosine, the pressure wire was slowly pulled back from the most distal to the proximal part of the artery by manual pullback. The following measurements were performed before and after PCI (Figure 1):

1. Baseline (FFR_{PRE}) – defined as evaluation of lesion significance prior to PCI, with the pressure wire sensor positioned at the beginning of the distal segment of the artery.
2. After PCI:
 - a. FFR_{POST} – after PCI the FFR was measured in the same position as FFR_{PRE} positioned at the beginning of the distal segment.
 - b. FFR gradient:
 - i. FFR gradient across the stent ($\text{GRAD}_{\text{STENT}}$) was defined as difference between FFR value just proximal to the stent and FFR value just distal to the stent.
 - ii. FFR gradient distal to stent ($\text{GRAD}_{\text{DISTAL}}$) was defined as difference between FFR value just distal to the stent and FFR value at the beginning of the distal segment.
 - iii. Total gradient was defined as difference between FFR value just proximal to the stent and FFR value at the beginning of the distal segment.
3. The same FFR values were obtained at 9-month follow-up (FFR_{FU} , $\text{GRAD}_{\text{StentFU}}$, $\text{GRAD}_{\text{DistalFU}}$).

Figure 1. FFR measurement (example).



If the patient was not on long-term dual antiplatelet therapy (DAPT), a loading dose of a P2Y12 inhibitor was given. All patients should have been pretreated with aspirin.

All study lesions were treated with Biolimus A9 (Biomatrix Flex, Biosensors, Newport Beach, California), Everolimus (Xience Xpedition, Abbott Vascular, IL) or Zotarolimus (Resolute Integrity, Medtronic Vascular, Santa Rosa, CA) drug eluting stents using the standard PCI technique. In this study the operators were encouraged to post dilate in every case.

After the PCI result was deemed adequate (TIMI III flow with a residual angiographic diameter stenosis of $\leq 20\%$), the FFR measurement was repeated and the final angiograms taken. An optimal functional result was defined as FFR value after PCI of >0.95 . A desirable result was defined as FFR value of >0.90 to 0.95 . Where FFR_{POST} was <0.95 , further post dilatation was mandatory. If there was a clear evidence of atheroma beyond the stented segment, the operator was encouraged to try to optimise the functional result further by implanting another stent more distally.

The value of cardiac biomarkers (Troponin I) was evaluated 12-24 hours after index PCI procedure for periprocedural MI screening.

After PCI all patients had medical therapy optimised as tolerated with all receiving dual antiplatelet therapy for a period of 12 months.

2.2. Definition of stent length

Based on previous work stent length was defined as long (30 to 49 mm; L-DES) and ultra-long defined as (≥ 50 mm; UL-DES) (17).

2.3. Follow-up

Patients were planned to undergo angiographic, FFR and clinical follow-up at 9 months and additional evaluation for clinical endpoints at 12 months and 2 years.

9-month follow-up was carried out during a visit to hospital with the clinical examination, control coronary angiography and FFR measurement (described in detail above).

The following clinical endpoints (MACE events) were evaluated:

1. Target vessel revascularization (TVR) – defined as any repeated percutaneous intervention of the target vessel or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion (18).
2. Non-target vessel revascularization – defined as any percutaneous intervention or bypass surgery of the non-target vessel.
3. Myocardial infarction:
 - a. periprocedural;
 - b. target vessel related;
 - c. non-target vessel related.
4. Definite stent thrombosis – defined as stent thrombosis, confirmed by coronary angiography or autopsy.
5. Death:
 - a. cardiac;
 - b. non-cardiac.

On angiographic evaluation, the same angiographic views were recorded as in the post-PCI stage. Angiographic restenosis was defined as a >50% diameter stenosis at a follow-up, as measured by quantitative coronary angiography (QCA).

The same FFR measurements as in the post-PCI stage were performed in the target vessel (described in detail above). FFR value ≤ 0.80 found at 9 months follow-up was defined as functional restenosis. Patients in whom the FFR_{POST} was ≤ 0.80 immediately after PCI, were excluded from the follow-up analysis of functional restenosis.

2-year follow-up was carried out as a telephone call to the patient or patient's general practitioner (in case the patient was unavailable). The same clinical endpoints as at 9 months were evaluated.

2.4. Quantitative coronary angiography (QCA)

QCA was retrospectively measured in all cases according to a standard protocol using QAngio XA 7.3 (Medis® medical imaging systems) software. The angiographic images taken before PCI, after PCI and at a follow-up stage were analyzed. The following variables were assessed and used for further statistical analysis:

1. Minimal luminal diameter (MLD) – the smallest in-segment lumen diameter derived from two orthogonal views.
2. Reference vessel diameter (RVD) – an average of the diameter of normal segments within 10 mm proximal and 10 mm distal to the target lesion from two orthogonal views.
3. Percent diameter stenosis (% DS) – the value calculated as $100 \times (1 - \text{MLD}/\text{RVD})$ using the mean values determined by QCA from two orthogonal views.
4. Acute gain – MLD assessed immediately after the PCI procedure minus MLD assessed before PCI.
5. Late lumen loss (LLL) – minimal luminal diameter (MLD) assessed at follow-up angiography minus the MLD assessed immediately after the PCI procedure.

2.5. Statistical analysis

Analysis was performed according to the intention-to-treat principle. Normal distribution was tested using the Kolmogorov-Smirnov test. Continuous variables with a normal distribution were compared using Student's t-test and presented as mean $\pm$ standard deviation (SD), otherwise, nonparametric Wilcoxon's signed-rank tests were used. Categorical variables were compared by using χ^2 or Fisher exact test and are presented as numbers or percentages. Multiple groups were compared by using a non-parametric Kruskal-Wallis test. Binary logistic regression analysis was performed to assess the associations of dichotomous dependent variables and independent variables. P value <0.05 was considered significant. Statistical analysis was performed with SPSS version 20.0 (SPSS, Inc., Chicago, IL, USA).

3. Results

3.1. Patient and procedure characteristics

A total of 74 patients were enrolled. All patients had significant ($\text{FFR} \leq 0.8$) lesions in at least one of the major coronary arteries. 71.6% of the patients presented with stable angina, 28.4% with acute coronary syndrome without ST segment elevation. The mean patient age was 67.8 ± 9.9 years, 73% of the patients were male. 21.6% of the patients had

diabetes mellitus, 90.5% hypertension, 81.1% hyperlipidemia. In 83.8% of the cases multivessel disease was present, 36.5% of the patients already had a previous revascularization event. Baseline demographic, clinical, lesion, and procedural characteristics are listed in detail in tables 1, 2 and 3 respectively.

Angiographic and functional assessment by FFR was performed in all 74 patients immediately before and after stent implantation. 61 lesions (82.4%) were in the left anterior descending artery (LAD), with the bigger proportion of LAD lesions in the longer stent (UL-DES) group (70.3% vs 94.6%, $p=0.01$). The mean lesion length was 39.04 ± 14.11 mm. 1.80 ± 0.62 stents per lesion were implanted. The mean stent length was $50.7\text{ mm}\pm14.6$ mm ranging between 30 mm to 98 mm with a median stent length of 49 mm indicating that this was indeed a cohort with long diffuse coronary artery disease. 37 patients (50.0%) had total stent length between 30 and 49 mm (L-DES group), 37 (50.0%) ≥ 50 mm (UL-DES group). The postdilatation with a non-compliant balloon to optimize stent deployment was performed in 82.4% of cases.

Patients were screened for procedure related myocardial damage. A slight postprocedural elevation of cardiac biomarker values was observed in all cases, 5 of them (6.8%) were classified as a PCI related MI according to the consensus criteria (19).

Table 1. Clinical characteristics of the patients.

	All patients n=74	L-DES (≤ 50 mm) n=37	UL-DES (> 50 mm) n=37	P value
Age, years	67.8 $\pm$ 9.9	66.8 $\pm$ 8.6	68.7 $\pm$ 9.9	0.63
Male sex	54 (73)	30 (81.1)	24 (64.9)	0.12
Current smoker	15 (20.3)	11 (29.7)	4 (10.8)	0.04
Diabetes mellitus	16 (21.6)	7 (18.9)	9 (24.3)	0.57
Hypertension	67 (90.5)	32 (86.5)	35 (94.6)	0.23
Hyperlipidemia	60 (81.1)	32 (86.5)	28 (75.7)	0.43
Previous revascularization	27 (36.5)	19 (51.4)	8 (21.6)	0.02
Previous myocardial infarction	27 (36.5)	17 (45.9)	10 (27.0)	0.09
Multivessel disease	62 (83.8)	33 (89.2)	29 (78.4)	0.35
Stable angina	53 (71.6)	27 (72.3)	26 (70.3)	0.79
ACS	21 (28.4)	10 (27.0)	11 (29.7)	0.64
LV ejection fraction	49.29 $\pm$ 7.77	48.96 $\pm$ 8.34	49.60 $\pm$ 7.35	0.78

Values are mean $\pm$ SD or n (%). ACS – acute coronary syndrome; LV – left ventricle.

Table 2. Procedural and QCA characteristics of the patients.

	All patients n=74	L-DES (≤ 50 mm) n=37	UL-DES (> 50 mm) n=37	P value
Pre-PCI				
RVD (mm $\pm$ SD)	2.47 $\pm$ 0.39	2.56 $\pm$ 0.40	2.37 $\pm$ 0.37	0.05
MLD (mm $\pm$ SD)	0.98 $\pm$ 0.24	1.06 $\pm$ 0.23	0.91 $\pm$ 0.22	0.01
Diameter stenosis (%)	59.90 $\pm$ 8.88	58.38 $\pm$ 9.00	61.48 $\pm$ 8.61	0.17
Post-PCI				
RVD (mm $\pm$ SD)	3.08 $\pm$ 0.46	3.09 $\pm$ 0.43	3.06 $\pm$ 0.49	0.81
MLD (mm $\pm$ SD)	2.59 $\pm$ 0.40	2.64 $\pm$ 0.41	2.55 $\pm$ 0.40	0.39
Diameter stenosis (%)	15.66 $\pm$ 5.18	14.70 $\pm$ 5.52	16.64 $\pm$ 4.69	0.14
Acute gain (mm $\pm$ SD)	1.61 $\pm$ 0.41	1.58 $\pm$ 0.42	1.64 $\pm$ 0.41	0.57
Follow-up				
RVD (mm $\pm$ SD)	2.95 $\pm$ 0.49	3.06 $\pm$ 0.53	2.84 $\pm$ 0.42	0.07
MLD (mm $\pm$ SD)	2.35 $\pm$ 0.46	2.46 $\pm$ 0.52	2.23 $\pm$ 0.36	0.04
Diameter stenosis (%)	20.29 $\pm$ 8.27	19.45 $\pm$ 8.75	21.17 $\pm$ 7.79	0.41
LLL (mm $\pm$ SD)	0.24 $\pm$ 0.41	0.17 $\pm$ 0.35	0.32 $\pm$ 0.46	0.17
Target Vessel LAD	61 (82.4)	26 (70.3)	35 (94.6)	0.01
Stent length, mm	50.72 $\pm$ 14.6	39.0 $\pm$ 5.6	62.4 $\pm$ 10.7	<0.001
Average stent diameter, mm	3.21 $\pm$ 0.36	3.36 $\pm$ 0.35	3.18 $\pm$ 0.32	0.08
Maximal implantation pressure, atm	14.09 $\pm$ 2.74	14.03 $\pm$ 2.3	14.11 $\pm$ 2.9	0.90
Post-dilatation	61 (82.4)	29 (78.4)	32 (86.5)	0.21
Maximal post-dilatation pressure, atm	18.31 $\pm$ 3.67	17.65 $\pm$ 3.50	18.97 $\pm$ 3.75	0.18

Values are mean $\pm$ SD or n (%). LAD – left anterior descending; atm – atmospheres.

Table 3. Stents used by type.

Stent type	No. (%)
Biolimus A9 eluting with biodegradable polymer	107 (80.5)
Zotarolimus eluting with durable polymer	16 (12.0)
Everolimus eluting with durable polymer	10 (7.5)

3.2. Baseline and post-PCI functional assessment

At baseline, the mean FFR_{PRE} was 0.61 $\pm$ 0.11. The mean FFR_{POST} immediately after the PCI increased to 0.88 $\pm$ 0.06 ($p < 0.001$) and was numerically higher in the L-DES group as compared to UL-DES (0.89 $\pm$ 0.07 vs. 0.87 $\pm$ 0.04; $p = 0.05$). An optimal FFR value of > 0.95 was achieved in only 9/74 patients (12.2%). Only 12/74 (16.2%) had a desirable FFR_{POST} of 0.91 to 0.95 inclusive. Finally, 53/74 (71.6%) had FFR values ≤ 0.90 . In 8/74 (10.8%) of the patients the FFR remained haemodynamically significant at ≤ 0.8 (mean

FFR_{POST} 0.77±0.04, mean stent length 50±15mm) indicating significant inducible ischaemia (Table 4).

Table 4. FFR at baseline, post-PCI, and at 9 months follow-up.

	All patients n=74	L-DES (≤50 mm) n=37	UL-DES (>50 mm) n=37	P value
Baseline (FFR_{PRE})	0.61±0.11	0.64±0.11	0.57±0.11	0.007
Post PCI	n=74	n=37	n=37	
FFR _{POST}	0.88±0.06	0.89±0.07	0.87±0.04	0.05
GRAD _{STENT}	0.06±0.03	0.04±0.03	0.07±0.03	0.001
GRAD _{DISTAL}	0.05±0.05	0.04±0.05	0.06±0.05	0.25
Follow-up	n=61	n=31	n=30	
FFR _{FU}	0.85±0.08	0.86±0.08	0.85±0.09	0.48
GRAD _{StentFU}	0.07±0.07	0.05±0.05	0.09±0.08	0.04
GRAD _{DistalFU}	0.05±0.04	0.05±0.05	0.04±0.03	0.38

3.3. FFR_{POST} in relation to stent length

At baseline, the mean FFR_{PRE} value was significantly lower in the UL-DES group compared to the L-DES group (0.57±0.11 versus 0.64±0.11, p=0.007)). Post PCI, the FFR_{POST} value remained numerically lower in the UL-DES group compared to the L-DES (0.89±0.07 vs. 0.87±0.04, p=0.05). An optimal FFR value of >0.95 was not achieved in any of the UL-DES patients (Figure 2, Table 4). A desirable FFR_{POST} value of >0.90 was achieved in only 21/74 patients (28.4%) of which 19 of those were from patients in the L-DES group and only 2 from the UL-DES group suggesting that even a desirable result is difficult to achieve in patients receiving Ultra Long stents. There was a low and inverse correlation between stent length and FFR after PCI (r = -0.297, p = 0.018) (Table 5).

Figure 2. Post-PCI functional results by FFR categories.




Table 5. The correlation between QCA measurements and functional results.

		FFR POST		FFR FU		GRAD Stent POST		GRAD Stent FU	
		<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>
MLD	baseline	-0.031	0.811	-0.015	0.909	-0.059	0.648	-0.140	0.287
	POST	0.115	0.369	0.160	0.222	-0.084	0.516	-0.233	0.074
RVD	baseline	0.138	0.280	0.172	0.189	-0.150	0.243	-0.207	0.113
	POST	0.101	0.433	0.147	0.264	-0.049	0.703	-0.168	0.200
Diameter stenosis	baseline	0.123	0.337	0.147	0.264	-0.032	0.804	0.002	0.989
	POST	-0.064	0.620	-0.051	0.700	0.185	0.149	0.226	0.083
Total stent lenght		-0.297	0.018	-0.024	0.858	0.480	<0.001	0.460	<0.001

r – Correlation coefficient; MLD – minimal luminal diameter; RVD – reference vessel diameter

3.4. FFR gradient

In the entire cohort the mean FFR GRAD_{Stent} was 0.06±0.03 and FFR GRAD_{Distal} was 0.05±0.05. The total gradient in patients that achieved an optimal result of FFR_{POST} of >0.95 after PCI was 0.02±0.02. Patients who remained haemodynamically significant after PCI (i.e. FFR≤0.8) had total gradient of 0.19±0.09. In these patients the GRAD_{Distal} was significantly higher than GRAD_{Stent} (0.11±0.07 vs. 0.08±0.02, p<0.0001)

(see Table 6), possibly indicating a more diffuse disease. GRAD_{Stent} was significantly higher in the UL-DES group compared to the L-DES group (0.07 ± 0.03 vs. 0.04 ± 0.03 ; $p=0.001$).

Table 6. GRAD_{Stent} and GRAD_{Distal} by FFR categories.

	All patients	≤ 0.8	0.81-0.9	0.91-0.95	>0.95	P value
Post-PCI	n=74					
GRAD _{Stent}	0.06 ± 0.03	0.08 ± 0.02	0.07 ± 0.03	0.04 ± 0.02	0.01 ± 0.01	<0.001
GRAD _{Dist}	0.05 ± 0.05	0.11 ± 0.07	0.05 ± 0.04	0.03 ± 0.03	0.01 ± 0.01	<0.001
Follow-up	n=61					
GRAD _{StentFU}	0.07 ± 0.07	0.08 ± 0.05	0.09 ± 0.08	0.04 ± 0.01	0.02 ± 0.01	<0.001
GRAD _{DistalFU}	0.05 ± 0.04	0.10 ± 0.06	0.05 ± 0.03	0.04 ± 0.02	0.01 ± 0.02	<0.001

3.5. At 9-month follow-up

At 9 months, coronary angiography was repeated in 64/74 (86.5%) patients with functional follow (FFR measurement) in 61/74 (82.4%) (Figure 3). The FFR values of these 61 patients were compared after PCI and at 9 months. A desirable FFR value of >0.90 decreased to 14/61 patients (23%) at 9-month follow-up. A proportion of patients remained to have haemodynamically significant disease increased to 12/61 patients (19.7%) (Figure 4). Restenosis rate was 3/64 (4.7%) by angio and 8/53 (15.1%) by functional assessment (Figure 5).

TVR rate was 6/74 (8.1%). One patient died during the first 9 months of the follow-up.

Figure 3. Patient flow chart.




Figure 4. Functional results at follow up by FFR categories.





Figure 5. Angiographic vs functional restenosis.



3.6. At 2-year follow-up

6 (8.1%) of the patients had ischemia driven TVR, all within the first 12 months (Figure 6). There were no definite stent thromboses and target vessel related acute coronary syndromes in the study group. At 2 years, the total MACE rate was 29.7%. Three (4.1%) cardiac deaths were reported, none of them was target vessel related (Table 7).

Table 7. Clinical endpoints at follow-up.

Clinical endpoints (N=74)	Up to 12 months, no. (%)	At 12-24 months, no. (%)	At 24 months, no. (%)
Death	2 (2.7%)	1 (1.3%)	3 (4.1%)
Cardiac	2 (2.7%)	1 (1.3%)	3 (4.1%)
Non-cardiac	0 (0%)	0 (0%)	0 (0%)
Myocardial infarction	5 (6.8%)	2 (2.7%)	7 (9.5%)
Periprocedural MI	5 (6.8%)	-	5 (6.8%)
Target vessel related MI	0 (0%)	0 (0%)	0 (0%)
Non-target vessel related MI	0 (0%)	2 (2.7%)	2 (2.7%)
Definite stent thrombosis	0 (0%)	0 (0%)	0 (0%)
Target vessel revascularization	6 (8.1%)	0 (0%)	6 (8.1%)
Other vessel revascularization	5 (6.8%)	3 (4.0%)	8 (10.8%)
Major adverse cardiac events	18 (24.3%)	4 (5.4%)	22 (29.7%)

The regression analysis was performed to evaluate the influence of the total stent length, reference vessel diameter, stent diameter, presence of diabetes on the clinical endpoints. There was no association between neither of these variables and MACE or TVR rates at 24 months. No independent predictors of TVR were identified (Table 8). There was a trend towards a higher TVR rate in patients with overlapping DES vs single DES implanted, though not statistically significant (9,6% vs 4,5%, $p=0.6$) (Figure 7).

Figure 6. TVR and total MACE during 2-year follow-up.




Figure 7. TVR rate in patients with overlapping DES vs single DES implanted.




Table 8. Independent Predictors of a 2-Year TVR.

Variable	OR (95% CI)	P value
Total stent length (per 10-mm increase)	0.96 (0.86-1.01)	0.41
Overlapping stent	2.23 (0.25-20.32)	0.48
Bifurcation lesion	3.44 (0.59-20.15)	0.17
RVD (per 0.2-mm increase)	0.74 (0.03-18.04)	0.85
MLD (per 0.5-mm increase)	0.43 (0.02-8.96)	0.58
NSD (per 0.25-mm increase)	0.03 (0.00-4.63)	0.17
Diabetes Mellitus	1.93 (0.32-11.62)	0.47

RVD – reference vessel diameter; MLD – minimal luminal diameter; NSD – nominal stent diameter; MACE – major adverse cardiovascular event; TVR – target vessel revascularization.

3.7. QCA analysis at baseline, after PCI and at 9-month follow-up

QCA analysis was performed with the dedicated QAngio XA 7.3 (Medis® medical imaging systems) software (Table 2). The pre-PCI reference vessel diameter (RVD) was 2.47 ± 0.39 mm, and was lower in UL-DES group as compared with L-DES (2.37 ± 0.37 mm vs 2.56 ± 0.40 mm respectively, $p=0.05$). A mean diameter stenosis was $59.9 \pm 8.9\%$. The post-PCI RVD was 3.08 ± 0.46 mm, acute gain 1.61 ± 0.41 mm, without significant difference between L-DES and UL-DES groups.

At the follow-up, the mean RVD was 2.95 ± 0.49 mm and was similar in L-DES and UL-DES groups. Mean minimal lumen diameter (MLD) was 2.35 ± 0.46 and was lower in UL-DES group (2.23 ± 0.36 vs 2.46 ± 0.52 , $p=0.04$).

Angiographic in-stent late lumen loss was 0.24 ± 0.41 mm, with a statistically non-significant trend to be higher in the UL-DES group (0.32 ± 0.46 mm vs 0.17 ± 0.35 mm, $p=0.17$).

4. Discussion

There are several key findings of this study, the first of which is that achieving an optimal post-PCI FFR result of >0.95 is only possible in a limited number of cases equating to 12.2%. In particular, an optimal FFR result of >0.95 could not be achieved in

any patient who was treated with >50mm of stent. Furthermore, the use of long and ultra-long stents resulted in a high proportion of patients with residual haemodynamically significant ischaemia defined as a $\text{FFR} \leq 0.80$, despite optimisation of the stent during the procedure. Finally, the rate of functional restenosis at 9 months follow-up was shown to be approximately 3 times higher than angiographic restenosis in this cohort.

This study evaluated the functional results that can be achieved in patients treated with 2nd or newer generation drug eluting stents for diffuse long coronary artery lesions. This data shows that achieving a functionally optimal or even desirable result in long coronary artery disease using long coronary stents can be very difficult, even when using newer generation drug eluting stents. Previous work shows that the measurement of the post-PCI FFR is an important predictor of MACE. Pijls et al. have shown that the higher the FFR value after PCI the lower the rate of MACE (6). This has been subsequently corroborated from a metaanalysis done by Johnson et al. suggesting that FFR provides important prognostic information (7).

There are several key differences between our findings and those seen in previous studies. Crucially, the metaanalysis by Johnson et al. shows that only 27% of the patients treated received a drug eluting stent as opposed to all patients in our cohort. Obviously, the former is not reflective of current practice as 2nd generation drug eluting stents and beyond are now more widely used, largely driven by the fact that angiographic restenosis is less of an issue compared to the levels of angiographic restenosis seen during the era of BMS and even 1st generation DES (20). Looking at the predictive value of FFR in the first studies, the stent length ranges on average between 16 and 20 mm and desirable results were achieved in a very significant proportion of patients who had PCI (6,21,22).

There are several lines of evidence to suggest that the optimal PCI result is achieved when the post-PCI FFR value is >0.95, comparable to that found in angiographically normal coronary arteries (0.97 ± 0.02 [0.92-1.0]) (4). Moreover, the evidence also shows that optimal FFR values >0.95 are associated with lower rates of MACE (6,7,21,22). Pijls et al. showed that the 6 month MACE rate in patients receiving bare metal stents was 4.9% when the FFR value was >0.95 compared to 5.5% when the FFR value was between 0.91-0.95. MACE rates increased significantly to 18.1% when the

FFR value was between 0.81-0.9; a threefold increase, and as high as 30% when the FFR value remained ≤ 0.80 (6). Subsequent studies have reproduced Pijls's findings but with a higher proportion of patients achieving FFR values >0.95 (21,22). An important difference in these more recent studies has been the higher use of drug eluting stents. With these cut offs in mind, we see that an optimal result defined as a FFR value of >0.95 was achieved in only 36% of the patients in the Pijls et al. trial, in contrast to only 12% in the current study. Even when we re-define a desirable post-PCI FFR threshold as >0.90 then the proportion rises to 68% in the Pijls study, however it remains disappointingly low at 28% in the current study despite aggressive post dilatation. This notable difference may be explained in part by the considerable additional diffuse atherosclerotic burden as well as stent length. The average stent length is approximately 3 fold longer in our study compared to that seen in Pijls study and that of subsequent studies mentioned above. This suggests that a functionally sub-optimal result as measured by FFR is much more likely to occur if one decides to treat long diffuse coronary artery disease with long drug eluting stents even when these are newer generation DES. In every case, where patients received >50 mm of stent an optimal FFR result >0.95 could not be achieved in any case in this study. Similarly, there were only 2 cases where patients achieved a desirable FFR value of >0.90 but ≤ 0.95 indicating that the goal of achieving a functionally optimal or even desirable result after PCI in long coronary artery disease was virtually impossible. In support of this, Honda et al. suggested that ultra long (>50 mm) second generation DES implantation should be avoided due to a higher risk of target lesion revascularization (TLR) (13.5%) at a long-term follow-up (23.2 ± 13.2 months) relative to long (20-50 mm) DES (TLR 7.2%) and short DES (<20 mm) (TLR 6.0%).

In contrast to achieving an optimal or desirable result after PCI, there remains a haemodynamically significant cohort ($FFR \leq 0.80$) in all study populations. The proportion of these patients was approximately 6% in Pijls's study rising to 11% in patients with long diffuse coronary disease, as was the case in the current study. Pijls postulated that this persistent ischaemic burden seen in his cohort probably reflected the under appreciated nature of diffuse disease that remains in the unstented segment of the coronary artery. This again is the most likely explanation in our population and in support of these findings, we found that the gradient in the distal vessel (i.e. the residual gradient distal to

the stent) increased significantly as post-PCI FFR values decreased. Furthermore and in contrast to the previous studies (23), the gradient across the actual stented segment itself actually increased as FFR values decreased despite aggressive post dilatation. Notably in the group of patients who remained ischaemic (i.e. $FFR \leq 0.80$) the gradient along the entire vessel was significantly higher than in the group of patients who had FFR values >0.80 . In the group with residual ischaemia the gradient in the distal vessel itself was the greatest contributor to the total gradient being significantly higher than the gradient across the stent, probably again reflecting the diffuse atherosclerotic burden in the entire vessel. In these patients it may be that despite 2nd generation DES that functionally optimal or even desirable results cannot be achieved, however it may be that adjuvant use of IVUS or OCT imaging could provide an insight into the degree of atherosclerotic burden as well as the causes of this residual in-stent FFR gradient and guide us how to improve functional results. In support of this, focal underexpansion of stents can be seen in as many as 35% of PCI cases when a stent >28 mm is used (24). Further support for this strategy comes from Fearon et al. who show that the absence of a hyperaemic residual pressure gradient is a prerequisite for optimal stent deployment. In this study the FFR gradient was higher in the UL-DES group (0.07 ± 0.03) in comparison to shorter stents (0.04 ± 0.03). This may reflect the altered shear environment within the long stented segment thereby possibly leading to MACE, however it will need a much larger study to prove this theory.

Historically many studies used angiographic assessment for a follow-up. In this study we found following angiographic assessment at 9 months that there was a restenosis rate of 4.7% in keeping with previous studies that have used 2nd generation DES (25). However, in this study we also performed a haemodynamic assessment at 9 months and found a functional restenotic rate of 15.1% equating to a 3-4 fold increase. This suggests that angiographic assessment potentially misses a significant proportion of patients and therefore we should not be surprised if MACE rates are higher particularly in cases where PCI has been performed in long diffuse coronary disease using long 2nd generation DES. Simply believing the angiographic result may not be sufficient in order to avoid MACE, and functional restenosis may be a better predictor of MACE.

While there have been studies using IVUS guidance to optimise stent implantation, thereby increasing minimal luminal diameter, this gain has not been shown

to achieve functionally better results as FFR was not measured. In the AVIO study the increase in MLD did not improve clinical endpoint (26). Honda et al. reported 13,5% TLR rate in a group of patients with stent length >50 mm (UL-DES) vs 6.0% in short stent group (<20 mm) vs 7.2% in 20-50 mm (L-DES) despite IVUS guidance (17). In the recent study Elgendy et al. reported that IVUS-guided percutaneous coronary intervention is superior to angiography-guided percutaneous coronary intervention in reducing the risk of major adverse cardiac events primarily because of reduction in the risk of ischemia-driven target lesion revascularization (27).

Some of the findings of this study may have been explained by the fact that the majority of the cases were diffuse diseases in the LAD. One might speculate that had there been a higher proportion of patients with RCA or LCx disease that more functional optimal results would have been achieved (2).

Our study shows a very significant rate of functional restenosis, however, because of relatively small study group we are underpowered to say what impact this will have on clinical endpoints. We reported a 2-year TVR rate of 8.1%. All TVR occurred within the first 12 months and reached the peak in the period of scheduled angiographic and FFR follow-up. There was no target vessel related events during the second year of a follow-up. The reported TVR rate in our study is higher than expected in general population, but it is comparable to the rates reported by Honda et al. with the long DES (7.2% when the total stent length was 20-50 mm and 13.5% with the stents $\geq$ 50 mm) (17). In support to the most studies with newer generation DES and in contrast to the studies with the first generation DES and BMS (11,12,28), there was no association between the total stent length and TVR rate at a follow-up. Though, there was a trend towards a higher TVR rates in patients with overlapping DES implanted (9,6% vs 4,5%), suggesting, that the double stent layer at the sites of stent overlap could possibly be related to a risk of DES restenosis. However, this difference was not statistically significant.

In contrast to the studies with the first generation DES, where the rate of the late stent thrombosis was >2% (29), there was no definite stent thrombosis reported in the current study. Considering the mean stent length >50 mm, we can assume, that the total length of newer generation DES implanted does not affect the long term patient safety.

5. Conclusions

- Achieving an optimal post-PCI FFR result in patients with long diffuse coronary artery disease is only possible in a limited number of cases equating to 12.2%. An optimal FFR result could not be achieved in any patient who was treated with >50 mm of stent.
- The use of long and ultra-long stents resulted in a high proportion of patients with residual haemodynamically significant ischaemia (10.8% of cases with post-PCI FFR ≤ 0.80).
- The rate of functional restenosis at 9 months follow-up was shown to be approximately 3 times higher than angiographic restenosis.
- TVR rate at 2 years was 8.1%.

6. Practical recommendations

- In the majority of cases diffuse coronary artery disease cannot be functionally effectively treated using long and ultra long drug eluting stents.
- For patients with diffuse coronary artery disease, particularly when the envisaged stent length exceeds 50 mm, other treatment options should be considered (CABG or medical therapy alone).
- Although considering a relatively low TVR rate at 2 years, PCI on long coronary lesions could be used as an option in the high CABG risk patients with diffuse coronary artery disease.

MIOKARDO REVASKULIARIZACIJOS EFEKTYVUMO ĮVERTINIMAS VYRAUJANT DIFUZINIAM ATEROSKLEROZINIAM ŠIRDIES VAINIKINIŲ ARTERIJŲ PAŽEIDIMUI

Santrauka

1. Įvadas

Difuzinės vainikinių arterijų ligos gydymas išlieka viena aktualiausių šiuolaikinės kardiologijos ir kardiochirurgijos problemų. Didėjant sergamumui koronarine širdies liga kartu padaugėjo ir pacientų, besikreipiančių dėl toli pažengusios difuzinės ligos formos. Nepaisant spartaus intervencinės kardiologijos technologijų tobulėjimo, ilgų širdies vainikinių arterijų pažeidimų stentavimo rezultatai nėra geri, o jų įvertinimo priemonės ir kriterijai nėra aiškiai apibrėžti. Klasikinė aortokoronarinių jungčių operacija dažnai taikoma kaip pirmo pasirinkimo revaskuliarizacijos metodas, tačiau esant difuzinei vainikinių arterijų ligai vis dar nėra aišku, kuris gydymo būdas būtų optimalus kiekvienam pacientui, kokios apimties intervenciją pasirinkti ir kaip įvertinti jos efektyvumą. Klinikinėje praktikoje dažniausiai vertinamas angiografinis ir klinikinis perkutaninės koronarinės intervencijos (PKI) rezultatas, tačiau daugeliu atvejų, kai yra difuzinis vainikinių arterijų pažeidimas, angiografijos duomenys neatspindi tikrosios vainikinių arterijų kraujotakos, o pagrindinis visų gydomųjų intervencijų tikslas yra atkurti adekvačią širdies raumens kraujotaką tiek ramybėje, tiek fizinio krūvio metu, o ne anatomicę kraujagyslių struktūrą. Nors šiuolaikinei diagnostikai yra taikomi tiek neinvaziniai, tiek invaziniai širdies raumens perfuzijos įvertinimo metodai, tačiau klinikinių tyrimų duomenų apie ilgalaikį funkcinį PKI rezultatą po ilgų vainikinių arterijų pažeidimų stentavimo beveik nėra. Ypač tai pasakytina apie naujesnės kartos vaistais dengtų stentų naudojimo rezultatus.

2. Darbo hipotezė, tikslas ir uždaviniai

Hipotezė:

Po ilgų vainikinių arterijų susiaurėjimų stentavimo, nepaisant pasiekto gero angiografinio rezultato (liekamoji stenozė $< 20\%$), funkcinis revaskuliarizacijos efektas išlieka nepakankamas (frakcinis tėkmės rezervas $\leq 0,8$).

Vėlyvuoju laikotarpiu po PKI dėl difuzinės neointimos proliferacijos ilgame stentuo tame segmente, net ir nesant angiografiškai reikšmingos restenozės, frakcinio tėkmės rezervo tyrimu daliai pacientų nustatoma funkcinė restenozė.

Tikslas:

Įvertinti perkutaninės koronarinės intervencijos rezultatą gydant ilgus vainikinių arterijų susiaurėjimus antros ir naujesnės kartos vaistais dengtais stentais, atliekant angiografinį ir funkcinį vainikinių arterijų kraujotakos ištyrimą.

Uždaviniai:

Taikant frakcinės tėkmės rezervo tyrimą įvertinti funkcinį ilgų vainikinių arterijų susiaurėjimų stentavimo antros ir naujesnės kartos vaistais dengtais stentais rezultatą iškart po PKI ir po 9 mėnesių.

Išsiaiškinti, kokiai daliai pacientų, stentuo jant ilgus vainikinių arterijų susiaurėjimus, galima pasiekti funkciškai optimalų rezultatą ($FTR > 0,95$).

Palyginti angiografinių ir funkcinį restenozų dažnį praėjus 9 mėnesiams po PKI.

Įvertinti dvejų metų klinikinius ilgų vainikinių arterijų susiaurėjimų stentavimo antros ir naujesnės kartos vaistais dengtais stentais rezultatus bei stentų ilgio įtaką vėlyviesiems kardiovaskuliniams įvykiams.

3. Darbo naujumas

Duomenų apie funkcinį (hemodinaminį) revaskuliarizacijos poveikį ligoniams, sergantiems difuzine vainikinių arterijų liga, beveik nėra. Iki šio darbo nebuvo atlikta naujesnės kartos vaistais dengtų stentų tyrimų, kuriuose ligoniams po ilgų vainikinių arterijų susiaurėjimų stentavimo FTR matavimu būtų įvertintas funkcinis stentavimo rezultatas tiek iškart po procedūros, tiek vėlyvuoju laikotarpiu. Šio tyrimo duomenys turėtų padėti parinkti optimalią revaskuliarizacijos taktiką ligoniams, sergantiems difuzine vainikinių arterijų liga.

4. Metodika

Šis tyrimas atliktas prospektyviaja metodika, įtraukiant visus pacientus, kuriems numatyta įtraukimo laikotarpiu buvo atlikta širdies vainikinių arterijų angiografija, jeigu jie atitiko toliau aprašytus įtraukimo kriterijus ir raštiškai patvirtino savo sutikimą dalyvauti tyrime. Tyrimui atlikti buvo gautas bioetikos komiteto leidimas.

Į tyrimą buvo traukiami pacientai, sergantys stabilia krūtinės angina arba ūminiu koronariniu sindromu be ST segmento pakilimo elektrokardiogramoje, kuriems vainikinių arterijų angiografijos metu nustatytas ilgas hemodinamai reikšmingas susiaurėjimas bent vienoje iš didžiųjų vainikinių arterijų. Numatomas stento ilgis, reikalingas padengti visą vainikinės arterijos pažeidimą, turėjo būti ≥ 30 mm. Hemodinaminis susiaurėjimų reikšmingumas vertintas atliekant frakcinio tėkmės rezervo tyrimą. Reikšmingais klasifikuoti tie vainikinių arterijų susiaurėjimai, už kurių išmatuotas frakcinis tėkmės rezervas buvo $\leq 0,8$.

Atlikti tokie frakcinio tėkmės rezervo matavimai:

1. Pradinis FTR (FTR_{PRE}) – vainikinės arterijos susiaurėjimo hemodinaminio reikšmingumo įvertinimas prieš PKI procedūrą. Spaudimų vielytės jutiklis pozicionuojamas distalinėje vainikinės arterijos dalyje.
2. FTR po PKI:
 - a. FTR_{POST} – frakcinės tėkmės rezervas matuojamas po stento implantavimo spaudimų vielytės jutiklį pozicionuojant toje pačioje kraujagyslės vietoje kaip ir prieš PKI.
 - b. FTR gradientas:
 - i. FTR gradientas per stentą ($GRAD_{STENT}$) – skirtumas tarp FTR reikšmės, išmatuotos proksimaliau implantuoto stento, ir FTR reikšmės už stento.
 - ii. FTR gradientas distaliau stento ($GRAD_{DISTAL}$) – skirtumas tarp FTR reikšmės, išmatuotos iškart už implantuoto stento, ir FTR reikšmės distalinėje vainikinės arterijos dalyje.

- iii. Bendras FTR gradientas – skirtumas tarp FTR reikšmės, išmatuotos proksimaliau implantuoto stento, ir FTR reikšmės distalinėje vainikinės arterijos dalyje.

3. Tie patys FTR matavimai atlikti ir per 9 mėnesių kontrolinį FTR tyrimą.

Pamatavus FTR ir nustatius reikšmingą vainikinės arterijos susiaurėjimą, prieš pradedant PKI procedūrą visi pacientai buvo įsotinti antiagregantais (P2Y₁₂ receptorių antagonistais – klopidoogreliu arba tikagreloru ir aspirinu). PKI procedūra buvo atliekama tipine metodika. Visiems į tyrimą įtrauktiems pacientams buvo naudojami biolimusu A9 (Biomatrix Flex, Biosensors, Newport Beach, California), everolimusu (Xience Xpedition, Abbott Vascular, IL) arba zotarolimusu (Resolute Integrity, Medtronic Vascular, Santa Rosa, CA) dengti stentai.

Pagal bendrą implantuotų stentų ilgį tolesnės rezultatų analizės tikslais pacientai buvo suskirstyti į dvi grupes: ilgų stentų grupė – bendras stentų ilgis nuo 30 mm iki 49 mm (L-DES) ir labai ilgų stentų grupė – bendras stentų ilgis ≥ 50 mm (UL-DES).

Praėjus 9 mėnesiams po PKI procedūros suplanuota atlikti kontrolinę vainikinių arterijų angiografiją su FTR tyrimu. Klinikinis pacientų įvertinimas (apsilankius pas kardiologą arba telefoniniu skambučiu) numatytas po 12 ir 24 mėnesių.

5. Rezultatai

Į tyrimą iš viso įtraukti 74 pacientai. Visiems jiems nustatyti reikšmingi (FTR $\leq 0,8$) pažeidimai bent vienoje iš didžiųjų vainikinių arterijų. 71,6 % pacientų diagnozuota stabili krūtinės angina, 28,4 % – ūminis koronarinis sindromas be ST segmento pakilimo. Vidutinis pacientų amžius $67,8 \pm 9,9$ metai.

Vidutiniškai vienam pacientui implantuota $1,80 \pm 0,62$ stento. Vidutinis stentuoto segmento ilgis $50,7 \pm 14,6$ mm (nuo 30 mm iki 98 mm, mediana 49 mm).

Prieš PKI procedūrą vidutinis išmatuotas FTR buvo $0,61 \pm 0,11$. Vidutinis FTR iškart po procedūros padidėjo iki $0,88 \pm 0,06$ ($p < 0,001$) ir trumpesnių stentų grupėje (L-DES) buvo šiek tiek didesnis, palyginti su ilgesnių stentų grupe (UL-DES), atitinkamai

$0,89 \pm 0,07$ ir $0,87 \pm 0,04$; $p = 0,05$. Optimali FTR reikšmė ($>0,95$) buvo pasiekta tik 9 iš 74 pacientų (12,2 %). 12 iš 74 pacientų (16,2 %) buvo pasiektas geras funkcinis rezultatas (FTR $> 0,90$, bet $\leq 0,95$). 53 iš 74 pacientų nustatyta FTR reikšmė $\leq 0,9$, iš jų 8 pacientams (10,8 %) po PKI FTR reikšmė išliko $\leq 0,8$. Šiems 8 pacientams revaskuliarizacija buvo funkciškai neveiksminga (vidutinis jų FTR $0,77 \pm 0,04$, vidutinis stentų ilgis 50 ± 15 mm).

Prieš perkutaninę koronarinę intervenciją FTR reikšmė UL-DES pacientų grupėje buvo mažesnė nei L-DES grupėje (atitinkamai $0,57 \pm 0,11$ ir $0,64 \pm 0,11$; $p = 0,007$). FTR matavimuose po PKI išliko ta pati tendencija (atitinkamai $0,87 \pm 0,04$ ir $0,89 \pm 0,07$; $p = 0,05$). Optimali FTR reikšmė ($>0,95$) nebuvo pasiekta nė vienam UL-DES grupės pacientui. Visoje tiriamųjų imtyje geras arba optimaus funkcinis rezultatas (FTR reikšmė $>0,90$) pasiektas 21 iš 74 pacientų (28,4 %), tačiau 19 iš jų priklausė L-DES grupei ir tik 2 buvo iš UL-DES grupės. Šie duomenys parodo, kad pasiekti gerą funkcinį rezultatą implantuojant ilgesnius kaip 50 mm stentus pavyksta tik labai mažai daliai pacientų.

Praėjus 9 mėnesiams po PKI, kontrolinė vainikinių arterijų angiografija buvo atlikta 64 iš 74 pacientų (86,5 %). Funkcinis įvertinimas matuojant frakcinį tėkmės rezervą atliktas 61 iš 74 pacientų (82,4 %). Tik šių 61 pacientų FTR reikšmės praėjus 9 mėnesiams lygintos su reikšmėmis, gautomis iškart po PKI. Pacientų, kuriems nustatytas geras PKI rezultatas (FTR $> 0,90$) per 9 mėnesius sumažėjo nuo 26,2 % (16 iš 61) iki 23 % (14 iš 61). Pacientų, kuriems po atliktos PKI vis dar nustatoma indukuojama miokardo išemija (FTR $\leq 0,8$) padaugėjo nuo 13,3 % (8 iš 61) iki 19,7 % (12 iš 61). Funkcinė restenozė (FTR sumažėjimas $\leq 0,80$, atmetus tuos tiriamuosius, kuriems FTR $> 0,80$ nebuvo pasiektas iškart po PKI) nustatyta 15,1 % pacientų.

Pakartotinių tiriamosios kraujagyslės revaskuliarizacijų dažnis per 9 mėnesių laikotarpį buvo 8,1 % (6 iš 74 pacientų).

Pakartotinių tiriamosios kraujagyslės revaskuliarizacijų dažnis per 24 mėnesių laikotarpį išliko 8,1 % (6 iš 74 pacientų), t. y. per antrus stebėjimo metus pakartotinių tiriamosios kraujagyslės revaskuliarizacijų nebuvo.

6. Išvados

Ligoniams, turintiems ilgus vainikinių arterijų pažeidimus, optimalus funkcinis revaskuliarizacijos rezultatas antros ir naujesnės kartos vaistais dengtais stentais pasiektas tik 12,2 % atvejų. Optimalaus funkcinio rezultato nepavyko pasiekti nė vienu atveju, kai stento ilgis buvo ≥ 50 mm.

Iškart po atliktos PKI 10,8 % atvejų išlieka indukuojama išemija gydytos vainikinės arterijos srityje (FTR $\leq 0,8$).

Per 9 mėn. laikotarpį po ilgų vainikinių arterijų pažeidimų PKI funkcinio restenozių dažnis yra daugiau kaip tris kartus didesnis nei angiografinių restenozių ir siekia 15,1 %.

Per dvejų metų laikotarpį po PKI pakartotinių tiriamos vainikinės arterijos revaskuliarizacijų dažnis siekia 8,1 %, visos jos atliktos per pirmus 12 mėnesių.

7. Apibendrintos išvados klinikinei praktikai

Esant difuzinei vainikinių arterijų ligai, ilgus vainikinių arterijų pažeidimus stentuojančios antros ir naujesnės kartos vaistais dengtais stentais, daugeliu atvejų funkcinis revaskuliarizacijos efektas nėra pakankamas.

Ligoniams, turintiems ilgus vainikinių arterijų pažeidimus, ypač kai numatomas stento ilgis ≥ 50 mm, svarstyti kiti gydymo taktika (chirurginė revaskuliarizacija atliekant aortokoronarinių jungčių operaciją arba medikamentinis gydymas).

Įvertinus santykinai nedidelį koronarinių įvykių dažnį per dvejų metų laikotarpį, gydymas PKI būdu taikytinas didelės rizikos pacientams, kuriems negalima atlikti chirurginės revaskuliarizacijos.

DOKTORANTO GYVENIMO APRAŠYMAS

Vardas Pavardė: Arvydas Baranauskas

Gimimo data: 1981 05 13

Darbovietė: VšĮ Vilniaus universiteto ligoninė Santaros klinikos, Kardiologijos ir angiologijos centras, gydytojas kardiologas – intervencinis kardiologas.

Adresas: Santariškių g. 2, 08661 Vilnius, Lietuva

El. paštas: arvydas.baranauskas@santa.lt

Išsilavinimas:

2012–2016 m. doktorantūros studijos VU Medicinos fakultete.

2012 m. 6 mėnesių stažuotė Orhuso universiteto Skejby ligoninėje Danijoje.

2006–2010 m. kardiologijos rezidentūra VU Medicinos fakultete, VšĮ Vilniaus universiteto ligoninėje Santariškių klinikose, įgyta gydytojo kardiologo profesinė kvalifikacija.

2005–2006 m. internatūra VšĮ Klaipėdos jūrininkų ligoninėje, įgyta medicinos gydytojo kvalifikacija.

1999–2005 m. studijos Vilniaus universiteto Medicinos fakultete pagal medicinos studijų krypties medicinos programą.

Publikacijos:

Baranauskas A, Peace A, Kibarskis A, Shannon J, Abraitis V, Bajoras V, Bilkis V, Aidietis A, Laucevičius A, Davidavičius G. FFR Result Post PCI is Suboptimal in Long Diffuse Coronary Artery Disease. *EuroIntervention*. 2016 Dec 20;12(12):1473-1480.

Baranauskas A, Bajoras V, Budrys P, Laucevičius A, Davidavičius G. FFR Guided PCI on Long Coronary Lesions: 2-Year Clinical Results With 2nd or Newer Generation DES. *Acta Medica Lituanica*. 2016. Vol. 23. No. 1. P. 5–10.

Maeng M, **Baranauskas A**, Christiansen EH, Kaltoft A, Holm NR, Krusell LR, Ravkilde J, Tilsted HH, Thayssen P, Jensen LO. 10-Month Angiographic and 4-Year Clinical Outcome of Everolimus-Eluting Versus Sirolimus-Eluting Coronary Stents in Patients With Diabetes Mellitus (the DiabeDES IV randomized angiography trial). *Catheter Cardiovasc Interv*. 2015 Dec 1;86(7):1161-7.

Tyrimų rezultatų sklaida:

Baranauskas A, Peace A, Kibarskis A, Shannon J, Abraitis V, Bajoras V, Bilkis V, Aidietis A, Laucevičius A, Davidavičius G. FFR Result Post PCI is Suboptimal in Long Diffuse Coronary Artery Disease Treated with 2nd or Newer Generation Drug Eluting Stents. Žodinis pranešimas tarptautinėje konferencijoje *EuroPCR 2016*, Paris, France, 17th-20th May, 2016.

Baranauskas A, Kibarskis A, Bajoras V, Samalavičius R, Abraitis V, Bilkis V, Aidietis A, Laucevičius A, Davidavičius G. FFR Guided PCI on Long Coronary Lesions: Functional Outcome at 9-Month Follow-Up. Stendinis pranešimas tarptautinėje konferencijoje *AATS International Coronary Congress*, New York, USA, August 21-23, 2015.

Baranauskas A, Davidavicius G, Bajoras V, Kibarskis A, Bilkis V, Laucevicius A. Predictive FFR Value After PCI on Long Coronary Lesions. Stendinis pranešimas tarptautinėje konferencijoje *Cardiovascular Research Technologies (CRT)2015*, Washington DC, USA, February 21-24, 2015.

Baranauskas A, Davidavičius G, Bajoras V, Kibarskis A, Bilkis V, Laucevičius A. Follow-up Results of Biolimus-eluting Biodegradable Polymer Stents in Long Coronary Lesions: Can We Predict the Outcomes? Stendinis pranešimas tarptautinėje konferencijoje *Evolutionary Medicine: Perspectives in Understanding Health and Disease*, 27th-30th May, 2014, Vilnius, Lithuania.

Baranauskas A, Davidavičius G, Kibarskis A, Bilkis V, Abraitis V, Laucevičius A. Biolimus-eluting Biodegradable Polymer Stent Performance in Long Coronary Lesions. Stendinis pranešimas tarptautinėje konferencijoje *EuroPCR 2014*, Paris, France, 20th-23th May, 2014.

Baranauskas A, Davidavičius G, Kibarskis A, Bilkis V, Abraitis V, Laucevičius A. FFR Guided PCI on Long Coronary Lesions: 9-month Follow-up Results. Žodinis pranešimas tarptautinėje konferencijoje *EuroPCR 2014*, Paris, France, 20th-23th May, 2014.

References

1. De Bruyne B, Fearon WF, Pijls NHJ, Barbato E, Tonino P, Piroth Z, et al. Fractional Flow Reserve-Guided PCI for Stable Coronary Artery Disease. *N Engl J Med*. 2014 Sep 25;371(13):1208–17.
2. Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, Vroey FD, et al. Evolving Concepts of Angiogram: Fractional Flow Reserve Discordances in 4000 Coronary Stenoses. *Eur Heart J*. 2014 Oct 21;35(40):2831–8.
3. Park S-J, Ahn J-M, Park G-M, Cho Y-R, Lee J-Y, Kim W-J, et al. Trends in the Outcomes of Percutaneous Coronary Intervention With the Routine Incorporation of Fractional Flow Reserve in Real Practice. *Eur Heart J*. 2013 Nov 14;34(43):3353–61.
4. Bruyne BD, Hersbach F, Pijls NHJ, Bartunek J, Bech J-W, Heyndrickx GR, et al. Abnormal Epicardial Coronary Resistance in Patients With Diffuse Atherosclerosis but ‘Normal’ Coronary Angiography. *Circulation*. 2001 Nov 13;104(20):2401–6.
5. Agarwal SK, Kasula S, Hacioglu Y, Ahmed Z, Uretsky BF, Hakeem A. Utilizing Post-Intervention Fractional Flow Reserve to Optimize Acute Results and the Relationship to Long-Term Outcomes. *JACC Cardiovasc Interv*. 2016 May 23;9(10):1022–31.
6. Pijls NHJ, Klauss V, Siebert U, Powers E, Takazawa K, Fearon WF, et al. Coronary Pressure Measurement After Stenting Predicts Adverse Events at Follow-Up A Multicenter Registry. *Circulation*. 2002 Jun 25;105(25):2950–4.
7. Johnson NP, Tóth GG, Lai D, Zhu H, Açar G, Agostoni P, et al. Prognostic Value of Fractional Flow Reserve: Linking Physiologic Severity to Clinical Outcomes. *J Am Coll Cardiol*. 2014 Oct 21;64(16):1641–54.
8. Bech GJ-W, De Bruyne B, Akasaka T, Liistro F, Bonnier HJ, Koolen JJ, et al. Coronary Pressure and FFR Predict Long-term Outcome After PTCA. *Int J Cardiovasc Intervent*. 2001 Jun;4(2):67–76.
9. Members AF, Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, et al. 2014 ESC/EACTS Guidelines on Myocardial Revascularization. *Eur Heart J*. 2014 Oct 1;35(37):2541–619.
10. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabaté M, et al. Drug-eluting Stent Thrombosis: Results From a Pooled Analysis Including 10 Randomized Studies. *J Am Coll Cardiol*. 2005 Mar 15;45(6):954–9.
11. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann F-J, Schömig A. Influence of Lesion Length on Restenosis After Coronary Stent Placement. *Am J Cardiol*. 1999 Jun 15;83(12):1617–22.

12. Habara S, Mitsudo K, Goto T, Kadota K, Fujii S, Yamamoto H, et al. The Impact of Lesion Length and Vessel Size on Outcomes After Sirolimus-eluting Stent Implantation for In-stent Restenosis. *Heart*. 2008 Jan 9;94(9):1162–5.
13. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes Associated With Drug-eluting and Bare-metal Stents: a Collaborative Network Meta-analysis. *The Lancet*. 2007 Sep 21;370(9591):937–48.
14. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice M-C, et al. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. *N Engl J Med*. 2007 Mar 8;356(10):998–1008.
15. Choi JJ, Koh Y-S, Lim S, Kim JJ, Chang M, Kang M, et al. Impact of the Stent Length on Long-Term Clinical Outcomes Following Newer-Generation Drug-Eluting Stent Implantation. *Am J Cardiol*. 2014 Feb 1;113(3):457–64.
16. Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, et al. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents: Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. *JACC Cardiovasc Interv*. 2011 Nov;4(11):1209–15.
17. Honda Y, Muramatsu T, Ito Y, Sakai T, Hirano K, Yamawaki M, et al. Impact of Ultra-Long Second-Generation Drug-Eluting Stent Implantation. *Catheter Cardiovasc Interv*. 2016 Feb 1;87(2):E44–53.
18. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Es G-A van, et al. Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions. *Circulation*. 2007 Jan 5;115(17):2344–51.
19. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, et al. Consideration of a New Definition of Clinically Relevant Myocardial Infarction After Coronary Revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). *J Am Coll Cardiol*. 2013 Oct 22;62(17):1563–70.
20. Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olivecrona G, Omerovic E, et al. Lower Risk of Stent Thrombosis and Restenosis With Unrestricted Use of ‘New-generation’ Drug-Eluting Stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). *Eur Heart J*. 2012 Mar 1;33(5):606–13.
21. Leesar MA, Satran A, Yalamanchili V, Helmy T, Abdul-Waheed M, Wongpraparut N. The Impact of Fractional Flow Reserve Measurement on Clinical Outcomes After Transradial Coronary Stenting. *EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol*. 2011 Dec;7(8):917–23.

22. Klauss V, Erdin P, Rieber J, Leibig M, Stempfle H-U, König A, et al. Fractional Flow Reserve for the Prediction of Cardiac Events After Coronary Stent Implantation: results of a multivariate analysis. *Heart*. 2005 Jan 2;91(2):203–6.
23. Veer M van't, Pijls NHJ, Aarnoudse W, Koolen JJ, Vosse FN van de. Evaluation of the Haemodynamic Characteristics of Drug-Eluting Stents at Implantation and at Follow-Up. *Eur Heart J*. 2006 Aug 1;27(15):1811–7.
24. Kang S-J, Mintz GS, Park D-W, Lee S-W, Kim Y-H, Lee CW, et al. Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation Intravascular Ultrasound Analysis. *Circ Cardiovasc Interv*. 2011 Jan 2;4(1):9–14.
25. Raungaard B, Jensen LO, Tilsted H-H, Christiansen EH, Maeng M, Terkelsen CJ, et al. Zotarolimus-Eluting Durable-Polymer-Coated Stent Versus a Biolimus-Eluting Biodegradable-Polymer-Coated Stent in Unselected Patients Undergoing Percutaneous Coronary Intervention (SORT OUT VI): a randomised non-inferiority trial. *The Lancet*. 2015 Apr 24;385(9977):1527–35.
26. Chieffo A, Latib A, Caussin C, Presbitero P, Galli S, Menozzi A, et al. A Prospective, Randomized Trial of Intravascular-Ultrasound Guided Compared to Angiography Guided Stent Implantation in Complex Coronary Lesions: The AVIO trial. *Am Heart J*. 2013 Jan;165(1):65–72.
27. Elgendy IY, Mahmoud AN, Elgendy AY, Bavry AA. Outcomes With Intravascular Ultrasound-Guided Stent Implantation: A Meta-Analysis of Randomized Trials in the Era of Drug-Eluting Stents. *Circ Cardiovasc Interv*. 2016 Apr;9(4):e003700.
28. Smits PC, Vlachojannis GJ, McFadden EP, Roylaards K-J, Wassing J, Joesoef KS, et al. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). *JACC Cardiovasc Interv*. 2015 Aug 17;8(9):1157–65.
29. Kufner S, Byrne RA, Valeskini M, Schulz S, Ibrahim T, Hoppmann P, et al. Five-Year Outcomes from a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: final results from the ISAR-TEST 4 randomised trial. *EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol*. 2016 Mar 20;11(12):1372–9.